Laparoscopic Hepatectomy May Be Effective in CCA Care
FF-10502-01 Shows Promise in Cholangiocarcinoma Clinical Trial
Study Identifies Potential Biomarkers for Early CCA Diagnosis
Study Reviews Cholangiocarcinoma in Africa
New Nomogram May Assess Venous Thromboembolism Risk in CCA
Cytotoxic and Noncytotoxic Chemotherapy May Be Similar for CCA
Percutaneous Ablation May Lead to Favorable Disease Control in iCCA
The Use of Immunotherapies Examined in CCA
Asbestos Exposure May Be Related to Small-Duct Intrahepatic Cholangiocarcinoma
Latest Clinical Trials
Targeting DNA Damage Response as a Therapeutic Strategy in CCA
Targeting DDR as emerged as a promising strategy for developing cancer-specific therapies. Here, we discuss the use of DDR inhibitors in CCA.
Understanding Diagnostic and Prognostic Biomarkers of Cholangiocarcinoma
Diagnostic and prognostic cholangiocarcinoma biomarkers can greatly help physicians in medical decision-making.
Intrahepatic Cholangiocarcinoma Recurrence: A Problem That Demands a Solution
Cancer recurrence remains a significant hurdle in our quest to find a cure for cancer. The question of why some patients experience recurrence while others do not still remains a mystery. At present, the approach to predicting recurrence is largely based on statistical data. Physicians can primarily refer to the risk of recurrence of a…
Understanding the Association Between Obesity and Cholangiocarcinoma
Studies have revealed that obesity is a significant risk factor for the development of cholangiocarcinoma.
The Practicalities of Genomic Profiling for Cholangiocarcinoma
Genomic profiling for cholangiocarcinoma and other cancers demonstrates significant evidence-based benefits, but faces practical hurdles.
Recent Changes in the Diagnosis and Treatment of Perihilar Cholangiocarcinoma
Over the last decade, medical research has led to significant progress in the diagnosis and treatment of perihilar cholangiocarcinoma.
Predicting the Prognosis of Patients With Intrahepatic Cholangiocarcinoma
Disease progression has a major impact on outcomes in patients with intrahepatic cholangiocarcinoma and many factors influence recurrence-free survival, studies have found.
The Expanding Role of Radiomics in Cholangiocarcinoma and Beyond
Many are heralding radiomics as the “next big thing” that will revolutionize medicine. We examine this claim, particularly when it comes to cholangiocarcinoma treatment.
At 40, Orphan Drug Act Enjoys Rare Bipartisan Support
Rare disease advocates are marking the 40th anniversary of the landmark Orphan Drug Act, which has led to over 1100 approvals for new therapies.
Vietnam Vets Face Higher Risk of Cholangiocarcinoma, Likely Due to Wartime Exposures
Hundreds of veterans who served in Vietnam in the 1960s and 1970s are now developing cholangiocarcinoma, likely due to exposure to liver flukes and dioxin.
Cholangiocarcinoma Foundation Hails FDA Approval of Durvalumab as a Milestone
Durvalumab (Imfinzi®) offers only a modest improvement in long-term survival rates for patients with cholangiocarcinoma, but it is big news.
An Inspirational Feat: Crossing Spain’s 500-Mile Camino de Santiago by Wheelchair
When 2 friends set out along Spain’s 500-mile Camino de Santiago, they didn’t know how many people they’d inspire with 3 little words: “I’ll Push You.”
Rare Care Podcast